Expression profile of CD10, Bcl-6, CD138, Bcl-2 and MUM1 and their prognostic value in 136 patients with diffuse large B-cell lymphoma
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
We evaluated the value of using a panel of GC B-cell (CD10 and Bcl-6) and activation (MUM1, CD138 and Bcl-2) markers by immunohistochemistry to define prognosis in patients with diffuse large B-cell lymphoma (DLBCL).
Two different models (Hans’ and modified Chang’s model) were applied on 136 de novo DLBCL patients. Median follow-up in all patients was 39 months (range 5–80 months).
According to Hans’ model, patients with GCB had much better overall survival (5-year OS, 75%) than those with non-GCB (5-year OS, 52%) (Kaplan-Meier survival analysis, P < 0.05, log rank test). According to modified Chang’s model, patients with group 1 had much better overall survival (5-year OS, 78%) than those with group 3 (5-year OS, 44%) while group 2 had no significant value compared with group 1 and group 3 in prognosis (Kaplan-Meier survival analysis, P < 0.05, log-rank test). Using multivariate Cox proportional hazards regression analysis, the international prognostic index scores (IPI), expression of CD138 and the expression pattern of modified Chang’s model were independent prognostic indicators.
Our results suggest that the expression patterns of the panel of GCB-cell and activation markers by immunohistochemistry correlate with prognosis of patients with DLBCL and both models can be used well in ordinary work.
- Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon: IARC Press, 2001. 127–130.
- Pileri SA, Dirnhofer S, Went P, et al. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology, 2002, 41: 482–509. CrossRef
- Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood, 2005, 106: 1164–1174. CrossRef
- Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med, 1993, 328: 1002–1006. CrossRef
- Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med, 1995, 333: 1540–1545. CrossRef
- The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med, 1993, 329: 987–994. CrossRef
- Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403: 503–511. CrossRef
- Rosenwald A, Wright G, Chan W, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med, 2002, 346: 1937–1947. CrossRef
- Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103: 275–282. CrossRef
- Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma. Am J Surg Pathol, 2004, 28: 464–470. CrossRef
- Liu YH, Xu FP, Zhuang HG, et al. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol, 2008, 39: 875–884. CrossRef
- Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Stein H Swerdlow. Elisa Campo, eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008. 233–244.
- Segal MR. Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited. Biostatistics, 2006, 7: 268–285. CrossRef
- Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood, 2002, 99: 1136–1143. CrossRef
- McClintock S, Perkins SL, Cleveland RP, et al. Immunohistochemical expression pattern of germinal center and activation B-cell markers correlates with prognosis in diffuse large B-cell lymphoma. Mod Pathol, 2003, 16: 244a.
- Colomo L, López-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 2003, 101: 78–84. CrossRef
- Linderoth J, Jerkeman M, Cavallin-Stahl E, et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res, 2003, 9: 722–728.
- Zinzani PL, Dirnhofer S, Sabattini E, et al. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica, 2005, 90: 341–347.
- Dogan A, Bagdi E, Munson P, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol, 2000, 24: 846–852. CrossRef
- Uherova P, Ross CW, Schnitzer B, et al. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol, 2001, 115: 582–588. CrossRef
- Xu Y, McKenna RW, Molberg KH, et al. Clinicopathologic Clinicopathologic analysis of CD10 and bcl-2 diffuse large B-cell lymphoma: identification of a high-risk subset with coexpression of CD10 and Bcl-2. Am J Clin Pathol, 2001, 116: 183–190. CrossRef
- Chang CC, Cleveland RP, Perkins SL. CD10 expression and survival. Am J Clin Pathol, 2002, 117: 660–661.
- Zhang A, Ohshima K, Sato K, et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Int, 1999, 49: 1043–1052. CrossRef
- Takeshita M, Iwashita A, Kurihara K, et al. Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma. Am J Surg Pathol, 2000, 24: 1641–1649. CrossRef
- Shiozawa E, Yamochi-Onizuka T, Takimoto M, et al. The GCB subtype of diffuse large B-cell lymphomais less frequent in Asian countries. Leuk Res, 2007, 31: 1579–1583. CrossRef
- Expression profile of CD10, Bcl-6, CD138, Bcl-2 and MUM1 and their prognostic value in 136 patients with diffuse large B-cell lymphoma
The Chinese-German Journal of Clinical Oncology
Volume 8, Issue 10 , pp 585-591
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- diffuse large B-cell lymphoma
- GC B-cell
- activated B-cell
- Author Affiliations
- 1. Department of Pathology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, 100021, China
- 2. Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, 100021, China